T2	Participants 166 210	autistic children in an ongoing double-blind
T1	Participants 30 72	learning and behavior in autistic children
T3	Participants 246 364	Children were randomly assigned to haloperidol-placebo-haloperidol or placebo-haloperidol-placebo treatment sequences.
T4	Participants 380 461	haloperidol was significantly superior to placebo in reducing behavioral symptoms
T5	Participants 500 588	children receiving haloperidol learned the discrimination while those on placebo did not
T6	Participants 590 684	Discrimination attained on haloperidol was retained when the children were switched to placebo
